Healthcare Equipment and Supplies
Company Overview of PharmaJet, Inc.
PharmaJet, Inc., a medical device company, develops and markets needle-free injection technology to deliver drugs and vaccines to intramuscular, subcutaneous, and intradermal tissue depths. It provides PharmaJet needle-free system that delivers liquid medications at high speed creating a ‘liquid jet’ to penetrate the skin and deliver the medicine through the skin. The company serves individual patients and public health needs in the United States and internationally. PharmaJet, Inc. was incorporated in 2005 and is based in Golden, Colorado with locations in Denver, Colorado; San Francisco, California; and Baltimore, Maryland.
400 Corporate Circle
Golden, CO 80401
Founded in 2005
Key Executives for PharmaJet, Inc.
President and Chief Operating officer
Chief Financial Officer and Vice President
Design & Production Chief
Global Head of Applications Development
Compensation as of Fiscal Year 2014.
PharmaJet, Inc. Key Developments
FDA Approves Use of AFLURIA Influenza Vaccine with PharmaJet, Inc.'s Needle-Free Injector
Aug 19 14
PharmaJet, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet Stratis(R) 0.5mL Needle-Free Jet Injector for delivery of AFLURIA in individuals aged 18 to 64 years. This is the first needle-free delivery system approved by the FDA for the administration of an inactivated influenza vaccine. Needlestick injuries pose a serious risk to healthcare workers who administer vaccinations and manage sharps disposal. Among retail pharmacists alone, a National Institute for Occupational Safety and Health study reveals that the incidence of needlestick injury is up to 3.62 per 100,000 vaccinations administered. PharmaJet's needle-free injection technology eliminates needlestick injuries, needle re-use and potential cross contamination, as well as reduces sharps waste management and disposal costs.
PharmaJet, Inc. Enters into Strategic Collaboration with CSL Ltd. for Needle-Free Delivery of Influenza Vaccines
Nov 29 12
PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria(R) influenza vaccine to be delivered with the PharmaJet Stratis(R) needle-free jet injector, as soon as the 2013-2014 flu season. Adding PharmaJet jet injectors to the Afluria(R) label will expand the delivery options for flu vaccine administration, thereby helping to broaden immunization coverage. The Centers for Disease Control and Prevention recommends an annual flu vaccination for all US citizens over 6 months old. Flu shots have proven to reduce illness, absenteeism and flu-related medical expenses. For many people, the fear of needles is enough to deter receiving a seasonal flu shot, despite the risk of contracting and spreading the illness. Afluria(R), is a non-adjuvanted seasonal influenza vaccine sold in two different formulations: thimerosal-free, pre-filled syringes, and in multi-dose vials. CSL Biotherapies and PharmaJet are working to include jet injectors as a method of administration on the Afluria(R) label in time for the 2013-2014 flu season. PharmaJet's collaboration with CSL involves conducting a Phase IV clinical study to demonstrate the immunogenicity and safety of Afluria(R), presented in multi-dose vials, when administered with PharmaJet Stratis(R) needle-free device. Pending favorable clinical results, CSL will submit a Supplement to Afluria(R)'s BLA to include the option of needle-free jet injection on the Afluria(R) labeling.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 19, 2014
Most Searched Private Companies
Sponsored Financial Commentaries